Clinical Trials Logo

Malignant Melanoma clinical trials

View clinical trials related to Malignant Melanoma.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT02275416 Active, not recruiting - Malignant Melanoma Clinical Trials

Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

Start date: February 2, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This study, with 20 patients participating, will examine the safety and tolerability for the ipilimumab/UV1 combination in patients with unresectable or metastatic malignant melanoma.

NCT ID: NCT02068196 Active, not recruiting - Malignant Melanoma Clinical Trials

A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.

Ipi4
Start date: January 2014
Phase: Phase 4
Study type: Interventional

The goal of this study is to understand how ipilimumab is being used, its safety profile, and the manner in which Adverse Reactions are managed in routine clinical practice. Another goal is to identify predictive biomarkers. The study is an observational study and not intended to test any hypothesis, but can be hypothesis generating.

NCT ID: NCT01167998 Active, not recruiting - Malignant Melanoma Clinical Trials

Early Diagnosis of Malignant Transformation of Pigmentary Skin Lesions

Start date: July 2010
Phase:
Study type: Observational

Malignant Melanoma is a deadly skin cancer that can be cured if diagnosed early. To date atypical pigmented skin lesions are diagnosed by appearance alone and many moles and lesions are excised unnecessarily and on the other hand malignant lesions are missed and diagnosed too late. In this study a protein conjugated to a florescent dye is spread on a suspicious pigmented lesion, the hypothesis is that this protein binds to malignant cells only and thus with a special camera that picks up the dye we can find pigmented lesions with early malignant transformation.

NCT ID: NCT00949702 Active, not recruiting - Malignant Melanoma Clinical Trials

A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma

Start date: October 2009
Phase: Phase 2
Study type: Interventional

This open-label single arm study will assess the efficacy, safety and tolerability of Vemurafenib in previously treated patients with metastatic melanoma. Patients will receive oral Vemurafenib [RG7204; PLEXXIKON: PLX4032] at a dose of 960 mg b.i.d. continuously until disease progression or withdrawal from study and will be assessed at regular intervals for tumour response and tolerability. Target sample size is <100 patients.

NCT ID: NCT00539591 Active, not recruiting - Malignant Melanoma Clinical Trials

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Start date: May 9, 2008
Phase: Phase 2
Study type: Interventional

The main goal of this study is to estimate the tumor response rate of temozolomide administered in combination with peginterferon alfa-2b to pediatric patients with unresectable Stage III, metastatic, or recurrent cutaneous melanoma.

NCT ID: NCT00052156 Active, not recruiting - Malignant Melanoma Clinical Trials

Vaccine Therapy for Patients With Stage IV Melanoma

Start date: n/a
Phase: Phase 3
Study type: Interventional

This is a Phase III study in patients with melanoma that has spread to the lymph nodes and/or a distant organ, and who have had all of their cancer surgically removed. The purpose of this study is to evaluate the ability of the CancerVax™ vaccine to prevent or slow the recurrence of melanoma.

NCT ID: NCT00052130 Active, not recruiting - Malignant Melanoma Clinical Trials

Vaccine Therapy for Patients With Stage III Melanoma

Start date: n/a
Phase: Phase 3
Study type: Interventional

This is a Phase 3 study in patients with melanoma that has spread to the lymph nodes (stage III), and who have had all of their cancer surgically removed. The purpose of this study is to evaluate the ability of the CancerVax™ vaccine to prevent or slow the recurrence of melanoma.